Our mission is to save lives through microbial restoration. Through our partnership with the University of Minnesota Microbiota Therapeutics Program, we developed the first stool donor program and are the only academic program in the world that is manufacturing therapeutic microbiota in accordance with Good Manufacturing Practice protocols, a requirement for all pharmaceutical products. To date, we have produced over 13,000 capsules used to treat C. difficile patients and to target illnesses in clinical trials across the country.
Clostridium difficile is an antibiotic resistant infection that infects roughly 500,000 patients each year. ACT’s partnership with the University of Minnesota treats C. difficile patients locally and provides therapeutics to providers around the United States. Our therapeutics have treated over 1,000 patients with a 98% success curative rate against recurrent C. difficile infections.